文献速递痛风与晶体性关节病

痛风患者启动别嘌醇前进行HLA-B*58:01基因分型的成本效果分析

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究从英国国家卫生服务体系视角,评估痛风患者启动别嘌醇前进行HLA-B*58:01基因分型预防严重药物不良反应的成本效果。结论认为常规分型在英国不太可能具有成本效果,但检测或非布司他成本降低后有望改善。

核心结论

  • 在英国,痛风患者启动别嘌醇前常规进行HLA-B*58:01基因分型以降低药物不良反应发生率不太可能具有成本效果。
  • 随着基因分型成本降低以及未来更便宜的非布司他仿制药上市,分型策略有望变得具有成本效果。

研究设计与样本

  • 系统综述与荟萃分析评估HLA-B*58:01与皮肤及超敏药物不良反应的关联,并以此构建决策分析和马尔可夫模型。
  • 从英国国家卫生服务体系视角估计分型策略与标准诊疗(检测阳性者处方非布司他)相关的终生成本和结局。
  • 通过情景分析评估替代治疗假设和不同患者人群。

主要发现

  • 分型策略带来的成本增加为103英镑(95%中心范围:98至106英镑),QALY增益为0.0023(95%中心范围:-0.0006至0.0055)。

临床怎么用

  • 在英国医疗体系中,不建议将HLA-B*58:01基因分型作为痛风患者启动别嘌醇前的常规策略。
  • 当基因分型或非布司他成本下降时,可重新评估分型策略的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether prospective testing for HLA-B*58:01, as a strategy to prevent serious adverse reactions to allopurinol in patients with gout, is cost-effective from the perspective of the National Health Service in the UK. METHODS: A systematic review and meta-analysis for the association of HLA-B*58:01 with cutaneous and hypersensitivity adverse drug reactions informed a decision analytic and Markov model to estimate lifetime costs and outcomes associated with testing vs standard care (with febuxostat prescribed for patients who test positive). Scenario analyses assessed alternative treatment assumptions and patient populations. RESULTS: The number of patients needed to test to prevent one case of adverse drug reaction was 11 286 (95% central range (CR): 2573, 53 594). Cost and quality-adjusted life-year (QALY) gains were small, £103 (95% CR: £98, £106) and 0.0023 (95% CR: -0.0006, 0.0055), respectively, resulting in an incremental cost-effectiveness ratio (ICER) of £44 954 per QALY gained. The probability of testing being cost-effective at a threshold of £30 000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30 000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38 478 per QALY gained. CONCLUSION: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Plumpton CO, Alfirevic A, Pirmohamed M, et al. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout. Rheumatology (Oxford). 2017. PMID: 28957559. doi:10.1093/rheumatology/kex253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。